Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNX-5422 and Everolimus in Neuroendocrine Tumors
NCT02063958Phase 1Completed
- Sponsor
- Esanex, Inc.
- Start
- Feb 2014
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of snx-5422 in Neuroendocrine Neoplasm (NEN), small cell lung cancer (SCLC) and renal cell carcinoma (RCC), sponsored by Esanex, Inc. Primary endpoint: Dose Limiting Toxicities at 28 days. Started Feb 2014; status: completed.
02
Drugs
snx-5422
03
Conditions
Neuroendocrine Neoplasm (NEN)small cell lung cancer (SCLC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02063958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02063958.